Filtered By:
Condition: Arthritis

This page shows you your search results in order of date. This is page number 3.

Order by Relevance | Date

Total 1184 results found since Jan 2013.

Safety of JAK inhibitors: a real-life multicenter retrospective cohort study
CONCLUSION: Our real-life data confirm that JAKi are effective and carry a low risk of AESI, especially in patients that do not display cardiovascular risk factors at baseline. Our study could not identify differences between molecules and different profiles should be defined in larger prospective cohorts.PMID:37527867 | DOI:10.3899/jrheum.2023-0145
Source: J Rheumatol - August 1, 2023 Category: Rheumatology Authors: Marco Lanzillotta Nicola Boffini Elisa Barone Gilberto Cincinelli Maria Chiara Gerardi Nicoletta Luciano Maria Manara Nicola Ughi Oscar Massimiliano Epis Carlo Selmi Roberto Felice Caporali Lorenzo Dagna Source Type: research

Inflammation and immunomodulatory therapies influence the relationship between ATP-binding cassette A1 membrane transporter-mediated cholesterol efflux capacity and coronary atherosclerosis in rheumatoid arthritis
CONCLUSION: ABCA1-CEC associated with decreased atherosclerosis in patients with below-median baseline and time-averaged CRP and bDMARD use. Conversely, ABCA1-CEC associated with increased plaque in those with higher CRP, corticosteroid users, methotrexate nonusers, and bDMARD nonusers. While in well-treated and controlled disease ABCA1-CEC appears atheroprotective, in uncontrolled RA its action may be masked or fail to counteract the inflammation-driven proatherogenic state.PMID:37520890 | PMC:PMC10371792 | DOI:10.1016/j.jtauto.2023.100209
Source: Atherosclerosis - July 31, 2023 Category: Cardiology Authors: George A Karpouzas Bianca Papotti Sarah R Ormseth Marcella Palumbo Elizabeth Hernandez Maria Pia Adorni Francesca Zimetti Matthew J Budoff Nicoletta Ronda Source Type: research

Comparative Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for Recurrent Gout Flares and Gout-Primary Emergency Department Visits and Hospitalizations : A General Population Cohort Study
CONCLUSION: Among patients with gout, SGLT2is may reduce recurrent flares and gout-primary ED visits and hospitalizations and may provide cardiovascular benefits.PRIMARY FUNDING SOURCE: National Institute of Arthritis and Musculoskeletal and Skin Diseases.PMID:37487215 | DOI:10.7326/M23-0724
Source: Annals of Internal Medicine - July 24, 2023 Category: Internal Medicine Authors: Natalie McCormick Chio Yokose Jie Wei Na Lu Deborah J Wexler J Antonio Avi ña-Zubieta Mary A De Vera Yuqing Zhang Hyon K Choi Source Type: research

Statins influence the relationship between ATP-binding cassette A1 membrane transporter-mediated cholesterol efflux capacity and coronary atherosclerosis in rheumatoid arthritis
CONCLUSION: In patients with RA, higher ABCA1-CEC may reflect a proatherogenic state, associated with enhanced cardiovascular risk. Statin use may unmask the protective impact of ABCA1-mediated cholesterol efflux on plaque formation, progression and cardiovascular risk.PMID:37484708 | PMC:PMC10362327 | DOI:10.1016/j.jtauto.2023.100206
Source: Atherosclerosis - July 24, 2023 Category: Cardiology Authors: George A Karpouzas Bianca Papotti Sarah R Ormseth Marcella Palumbo Elizabeth Hernandez Maria Pia Adorni Francesca Zimetti Matthew J Budoff Nicoletta Ronda Source Type: research